Recombinant Human Interleukin-1 Receptor Antagonist, Anakinra, to Prevent Post-Infarction Remodeling: the Virginia Commonwealth University Anakinra Remodeling Trial (VCU-ART).

Trial Profile

Recombinant Human Interleukin-1 Receptor Antagonist, Anakinra, to Prevent Post-Infarction Remodeling: the Virginia Commonwealth University Anakinra Remodeling Trial (VCU-ART).

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2014

At a glance

  • Drugs Anakinra (Primary)
  • Indications Heart failure; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms VCU-ART
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 May 2010 Results have been published (American Journal of Cardiology 105: 1371-1377.e1, No. 10, 15 May 2010).
    • 16 Mar 2010 Results presented at the 59th Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top